ReviewCurrent problems in cardiology2022
Peripheral Artery Disease and COVID-19 Outcomes: Insights from the Yale DOM-CovX Registry.
Review in Current problems in cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2024Guideline
- Guideline
- Smartphone-based Assessment of Vasomotor Function via Fingertip Arteriolar Elasticity Using the Volume-Oscillometric Method with Green Light Photoplethysmography.Annals of biomedical engineering · 2026Article
- Machine learning identifies clinical and sociodemographic factors contributing to post-COVID hospitalization and cardiovascular risk in patients with peripheral artery disease.Scientific reports · 2025Article
- Trends and disparities in mortality associated with peripheral artery disease and hyperlipidemia, 1999-2024.Scientific reports · 2025Article
- Global, regional, and national burden of lower extremity peripheral arterial disease: a systematic analysis of prevalence, incidence, deaths, and dalys from 1990 to 2021 with projections and dietary risk factors to 2036.Journal of health, population, and nutrition · 2025Article
- Arteriolar Elasticity Measurement in the Fingertip Based on Photoplethysmographic Volume-Oscillometry: A New Approach to the Assessment of Vasomotor Functions in the Microvasculature.Cardiovascular engineering and technology · 2025Article
- Two year comparative outcomes of drug coated balloons in long versus short femoropopliteal lesions.Scientific reports · 2025Article
- Impact of the COVID-19 pandemic on patients with peripheral arterial disease in China: a multicenter cross-sectional study.Scientific reports · 2024Article
- Chronic Obstructive Pulmonary Disease and the Omicron Variant of COVID-19 Prognosis: A Retrospective Cohort Study.Cureus · 2024Article
- Identification and Prediction of Clinical Phenotypes in Hospitalized Patients With COVID-19: Machine Learning From Medical Records.JMIR formative research · 2023Article
- Evaluation of the Risk Factors for Cellulitis among Patients with Peripheral Artery Disease.Medicina (Kaunas, Lithuania) · 2023Article
- Distinct Features of Vascular Diseases in COVID-19.Journal of inflammation research · 2023Review
- COVID-19 mortality prediction using ensemble learning and grey wolf optimization.PeerJ. Computer science · 2023Article
- Pulmonary Embolism Severity Index Predicts Adverse Events in Hospitalized COVID-19 Patients: A Retrospective Observational Study.Journal of cardiothoracic and vascular anesthesia · 2022Observational
- Acute and Long-Term Consequences of COVID-19 on Arterial Stiffness-A Narrative Review.Life (Basel, Switzerland) · 2022Review
- Cardiac Rehabilitation in Patients with Peripheral Artery Disease-A Literature Review in COVID-19 Era.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Both COVID-19 infection and peripheral arterial disease (PAD) cause hypercoagulability in patients, and it remains unknown whether PAD predisposes patients to experience worse outcomes when infected with SARS-CoV-2. The Yale DOM-CovX Registry consecutively enrolled inpatients for SARS-CoV-2 between March 1, 2020, and November 10, 2020. Adjusted logistic regression models examined associations between PAD and mortality, stroke, myocardial infarction (MI), and major adverse cardiovascular events (MACE, all endpoints combined). Of the 3830 patients were admitted with SARS-CoV-2, 50.5% were female, mean age was 63.1 ± 18.4 years, 50.7% were minority race, and 18.3% (n = 693) had PAD. PAD was independently associated with increased mortality (OR = 1.45, 95% CI 1.11-1.88) and MACE (OR = 1.48, 95% CI 1.16-1.87). PAD was not independently associated with stroke (P = 0.06) and MI (P = 0.22). Patients with PAD have a >40% odds of mortality and MACE when admitted with a SARS-CoV-2, independent of known risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.